A Review on Alzheimer’s disease and mesenchymal stem cell therapy

Aman Ullah; Saad Hanif Abbasi; Ismail Badshah; Komal Latif; Abdul Mateen; Adnan Aslam; Nafees Ur Rehman; Mansoor Anwar; Ahmed Hussain Bhutta; Muhammad Imran Khan

doi:10.32593/jstmu/Vol5.Iss1.190

Aman Ullah Saba Medical Center, Musaffah, Abu Dhabi, United Arab Emirates.
Saad Hanif Abbasi Department of Public Health, University of Southern Denmark, Odense, Denmark
Ismail Badshah Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
Komal Latif Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
Abdul Mateen Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
Adnan Aslam Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan
Nafees Ur Rehman Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
Mansoor Anwar Pakistan Air Force Hospital, Islamabad, Pakistan
Ahmed Hussain Bhutta Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan
Muhammad Imran Khan Department of Biomedical Sciences, Pak-Austria Fachhochschule: Institute of Applied Sciences and Technology, Mang Haripur, KPK, Pakistan

DOI: https://doi.org/10.32593/jstmu/Vol5.Iss1.190

Keywords: Alzheimer's disease, Beta amyloid, Neuroinflammation, Stem cells

Abstract

Alzheimer's disease (AD) is a progressive neurological ailment that manifests as difficulties in completing everyday activities, disorientation, and memory loss. Several innovative drug therapies have failed in clinical trials because they cannot stop or encourage the regeneration of injured brain cells. Furthermore, many medications only give symptomatic alleviation. As a result, a better knowledge of stem cell therapy's process might lead to new and effective treatments for this severe disease. Recent preclinical evidence suggests that stem cells can be used to treat or model AD. The mechanisms of stem cell based therapies for AD include stem cell mediated neuroprotection and trophic actions, antiamyloidogenesis, beneficial immune modulation, and the replacement of the lost neurons. This study examined the present status of many Mesenchymal stem cell-based therapeutics in AD pathogenesis. Furthermore, we have emphasized current clinical research that may be useful in treating Alzheimer's disease.

Downloads

Download data is not yet available.

Author Biographies

Aman Ullah, Saba Medical Center, Musaffah, Abu Dhabi, United Arab Emirates.

Pharmacist

Saad Hanif Abbasi, Department of Public Health, University of Southern Denmark, Odense, Denmark

Scholar

Ismail Badshah, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan

Researcher

Komal Latif, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan

Researcher

Abdul Mateen, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan

Researcher

Adnan Aslam, Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan

Researcher

Nafees Ur Rehman, Department of Pharmacology, Faculty of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan

Researcher

Mansoor Anwar, Pakistan Air Force Hospital, Islamabad, Pakistan

Pharmacist

Ahmed Hussain Bhutta, Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan

Instructor

Muhammad Imran Khan, Department of Biomedical Sciences, Pak-Austria Fachhochschule: Institute of Applied Sciences and Technology, Mang Haripur, KPK, Pakistan

Assistant Professor

References

Alzheimer's Association. 2012 Alzheimer’s disease facts and figures. Alzheimer's & Dementia. 2012; 8(2):131-68.

DOI: https://doi.org/10.1016/j.jalz.2012.02.001

Gauthier S, Scheltens P, Cummings J, editors. Alzheimer's Disease and Related Disorders. CRC Press; 2005.

WHO, Dementia. 2021. Available from :URL: https://www.who.int/news-room/fact-sheets/detail/dementia

Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer’s disease. Lancet 2016; 388:505-517.

DOI: https://doi.org/10.1016/S0140-6736(15)01124-1

Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. Bri Med J. 2019; 367.

DOI: https://doi.org/10.1136/bmj.l6217

Alzheimer's , 2020 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 202; 16(3)391-460.

DOI: https://doi.org/10.1002/alz.12068

Soria Lopez, J.A., H.M. González, and G.C. Léger, Chapter 13 - Alzheimer's disease, in Handbook of Clinical Neurology, Elsevier. 2019. 231-255.

Chakari-Khiavi F, Dolati S, Chakari-Khiavi A, Abbaszadeh H, Aghebati-Maleki L, Pourlak T, et al. Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment. Life Sci. 2019; 231:116564.

DOI: https://doi.org/10.1016/j.lfs.2019.116564

Mukhamedshina YO, Gracheva OA, Mukhutdinova DM, Chelyshev YA, Rizvanov AA. Mesenchymal stem cells and the neuronal microenvironment in the area of spinal cord injury. Neural Regen Res. 2019; 14(2):227.

DOI: https://doi.org/10.4103/1673-5374.244778

Yuan O, Lin C, Wagner J, Anderson JS, Archard JA, Deng P, et al., Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cells Dev, 2019; 28(6):398-409.

DOI: https://doi.org/10.1089/scd.2018.0200

Deng P, Anderson JD, Yu AS, Annett G, Fink KD, Nolta JA. Engineered BDNF producing cells as a potential treatment for neurologic disease. Expert Opin Biol Ther. 2016; 16(8):1025-33.

DOI: https://doi.org/10.1080/14712598.2016.1183641

Showalter MR, Wancewicz B, Fiehn O, Archard JA, Clayton S, et al. Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation. Biochem Biophys Res Commun. 2019; 512(4):729-35.

DOI: https://doi.org/10.1016/j.bbrc.2019.03.119

Park BW, Jung SH, Das S, Lee SM, Park JH, Kim H, et al. In vivo priming of human mesenchymal stem cells with hepatocyte growth factor–engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair. Sci Advances. 2020; 6(13):eaay6994.

DOI: https://doi.org/10.1126/sciadv.aay69

Park HH, Lee S, Yu Y, Yoo SM, Baek SY, Jung N, et al. TGF-β secreted by human umbilical cord blood-derived mesenchymal stem cells ameliorates atopic dermatitis by inhibiting secretion of TNF-α and IgE. Stem Cells. 2020; 38(7):904-16.

DOI: https://doi.org/10.1002/stem.3183

Ge X, Han Z, Chen F, Wang H, Zhang B, Jiang R, et al. MiR-21 alleviates secondary blood–brain barrier damage after traumatic brain injury in rats. Brain Res. 2015; 1603:150-7.

DOI: https://doi.org/10.1016/j.brainres.2015.01.009

Zhang F, Wang C, Wen X, Chen Y, Mao R, Cui D, et al. Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs‐mediated CD8+ T cell responses. J Cell Mol Med. 2020; 24(10):5817-31.

DOI: https://doi.org/10.1111/jcmm.15250

Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS. Intracerebral transplantation of bone marrow‐derived mesenchymal stem cells reduces amyloid‐beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells. 2010; 28(2):329-43.

DOI: https://doi.org/10.1002/stem.277

Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. Neurobiol Aging. 2012; 33(3):588-602.

DOI: https://doi.org/10.1016/j.neurobiolaging.2010.03.024

Li H, Liu CC, Zheng H, Huang TY. Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease–conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl Neurodegener. 2018; 7(1):1-6.

DOI: https://doi.org/10.1186/s40035-018-0139-3

Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712.

DOI: https://doi.org/10.1038/nrd3505

Murphy MP, LeVine III H. Alzheimer's disease and the amyloid-β peptide. J Alzheimer's Dis. 2010; 19(1):311-23.

DOI: https://doi.org/10.3233/JAD-2010-1221

Jha NK, Jha SK, Kar R, Nand P, Swati K, Goswami VK. Nuclear factor‐kappa β as a therapeutic target for Alzheimer's disease. J Neurochem. 2019; 150(2):113-37.

DOI: https://doi.org/10.1111/jnc.14687

Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005; 120(4):545-55.

DOI: https://doi.org/10.1016/j.cell.2005.02.008

Kumar P, Jha NK, Jha SK, Ramani K, Ambasta RK. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer's disease. J Alzheimers Dis. 2015; 43(2):341-61.

DOI: https://doi.org/10.3233/JAD-140933

Sardar Sinha M, Ansell-Schultz A, Civitelli L, Hildesjö C, Larsson M, Lannfelt L, et al. Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathol. 2018; 136(1):41-56.

DOI: https://doi.org/10.1007/s00401-018-1868-1

Brenowitz WD, Nelson PT, Besser LM, Heller KB, Kukull WA. Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. Neurobiol Aging. 2015; 36(10):2702-8.

DOI: https://doi.org/10.1016/j.neurobiolaging.2015.06.028

Prasanna P, Rathee S, Rahul V, Mandal D, Chandra Goud MS, Yadav P, et al. Microfluidic platforms to unravel mysteries of Alzheimer’s Disease: How far have we come?. Life. 2021; 11(10):1022.

DOI: https://doi.org/10.3390/life11101022

You Y, Perkins A, Cisternas P, Muñoz B, Taylor X, et al. Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathol Com. 2019; 7(1):1-5.

DOI: https://doi.org/10.1186/s40478-019-0680-z

Huang HC, Jiang ZF. Accumulated amyloid-β peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimer's Dis. 2009; 16(1):15-27.

DOI: https://doi.org/10.3233/JAD-2009-0960

Harvey RA, Ferrier DR. Lippincott’s illustrated reviews. Pharmacology. 2005;56.

Golan DE, Tashjian AH, Armstrong EJ, editors. Principles of pharmacology: the pathophysiologic basis of drug therapy. Lippincott Williams & Wilkins; 2011.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6.

DOI: https://doi.org/10.1126/science.107299

Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Ann Med. 2008; 40(8):562-83.

DOI: https://doi.org/10.1080/07853890802186905

Blurton-Jones M, LaFerla FM. Pathways by which Aβ facilitates tau pathology. Curr Alzheimer Res. 2006; 3(5):437-48.

DOI: https://doi.org/10.2174/156720506779025242

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003; 39(3):409-21.

DOI: https://doi.org/10.1016/S0896-6273(03)00434-3

Zheng XY, Wan QQ, Zheng CY, Zhou HL, Dong XY, Deng QS, et al. Amniotic mesenchymal stem cells decrease Aβ deposition and improve memory in APP/PS1 transgenic mice. Neurochem Res.. 2017; 42(8):2191-207.

DOI: https://doi.org/10.1007/s11064-017-2226-8

K Lee J, K Jin H, Bae JS. Bone marrow-derived mesenchymal stem cells attenuate amyloid β-induced memory impairment and apoptosis by inhibiting neuronal cell death. Current Alzheimer Res. 2010; 7(6):540-8.

DOI: https://doi.org/10.2174/156720510792231739

Salem AM, Ahmed HH, Atta HM, Ghazy MA, Aglan HA. Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats. Cell Biol. Int. 2014; 38(12):1367-83.

DOI: https://doi.org/10.1002/cbin.10331

Li A, Zhao J, Fan C, Zhu L, Huang C, Li Q, et al. Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging. 2020; 86:81-91.

DOI: https://doi.org/10.1016/j.neurobiolaging.2019.10.012

Ding M, Shen Y, Wang P, Xie Z, Xu S, Zhu Z, et al. Exosomes isolated from human umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in Alzheimer’s disease. Neurochem Res. 2018; 43(11):2165-77.

DOI: https://doi.org/10.1007/s11064-018-2641-5

Mehrabadi S, Motevaseli E, Sadr SS, Moradbeygi K. Hypoxic-conditioned medium from adipose tissue mesenchymal stem cells improved neuroinflammation through alternation of toll like receptor (TLR) 2 and TLR4 expression in model of Alzheimer's disease rats. Behav Brain Res. 2020; 379:112362.

DOI: https://doi.org/10.1016/j.bbr.2019.112362

Matchynski-Franks JJ, Pappas C, Rossignol J, Reinke T, Fink K, Crane A, Twite A, et al. Mesenchymal stem cells as treatment for behavioral deficits and neuropathology in the 5xFAD mouse model of Alzheimer's disease. Cell Transplant. 2016; 25(4):687-703.

DOI: https://doi.org/10.3727/096368916X690818

Yun HM, Kim HS, Park KR, Shin JM, Kang AR, Song S, et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1–42-infused mouse model of Alzheimer’s disease. Cell Death Differ. 2013; 4(12):e958.

DOI: https://doi.org/10.1038/cddis.2013.490

Cui GH, Guo HD, Li H, Zhai Y, Gong ZB, Wu J, et al. RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer’s disease. Immun Ageing. 2019; 16(1):1-2.

DOI: https://doi.org/10.1186/s12979-019-0150-2

Jiao H, Shi K, Zhang W, Yang L, Yang L, Guan F, et al. Therapeutic potential of human amniotic membrane-derived mesenchymal stem cells in APP transgenic mice. Oncol Lett. 2016; 12(3):1877-83.

DOI: https://doi.org/10.3892/ol.2016.4857

Zhao Y, Chen X, Wu Y, Wang Y, Li Y, Xiang C. Transplantation of human menstrual blood-derived mesenchymal stem cells alleviates Alzheimer’s disease-like pathology in APP/PS1 transgenic mice. Front Mol Neurosci. 2018:140.

DOI: https://doi.org/10.3389/fnmol.2018.00140

The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease. 2011 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT01297218.

The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD. 2012 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT01696591.

Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial. Alzheimer's & Dementia: Transl Res Clin Interv 2015; 1(2):95-102.

DOI: https://doi.org/10.1016/j.trci.2015.06.007

Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease (SEMAD). 2012 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT01547689.

Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease. 2014 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT02054208.

Jeong H, Kim OJ, Oh SH, Lee S, Reum Lee HA, Lee KO, et al. Extracellular Vesicles Released from Neprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer’s Disease Animal Model. Stem Cells Int. 2021; 2021.

DOI: https://doi.org/10.1155/2021/5548630

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease. 2017 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT03117738.

Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease. 2021 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT04482413.

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease. 2021 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/record/NCT04855955.

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease. 2016 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT02600130.

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease. 2016 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT02833792.

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease. 2020 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT04228666.

The Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease. 2021 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT04388982.

Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease. 2016 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT02899091.

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions. 2020 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT04684602.

Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease (SEESUPAD). 2017 [cited 2022; Available from: https://clinicaltrials.gov/ct2/show/NCT02672306..